tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Mar 8;S1201-9712(22)00145-X.
doi: 10.1016/j.ijid.2022.03.007. Online ahead of print.
Adverse events following coronavirus disease 2019 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study
Dong Seok Lee[SUP] 1 [/SUP], Ji Won Kim[SUP] 2 [/SUP], Kook Lae Lee[SUP] 3 [/SUP], Yong Jin Jung[SUP] 4 [/SUP], Hyoun Woo Kang[SUP] 5 [/SUP]
Affiliations
Abstract
Objectives: To investigate the clinical characteristics of adverse events following coronavirus disease 2019 (COVID-19) vaccination in patients in South Korea.
Design: Data from the Korean Disease Control and Prevention Agency on adverse events from four COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26 to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.
Results: Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 adverse events were reported. Most adverse events occurred after the first dose (80.6%) and within a day (63.2%) following vaccination. Of the adverse events, 95.5% were non-severe cases; however, 4.5% were severe. Most of the mild adverse events showed a similar frequency across all age groups, but major severe adverse events and mortality events increased with age.
Conclusions: Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in all four COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.
Keywords: COVID-19 vaccines; SARS-CoV-2; adverse events; vaccine reactions.
. 2022 Mar 8;S1201-9712(22)00145-X.
doi: 10.1016/j.ijid.2022.03.007. Online ahead of print.
Adverse events following coronavirus disease 2019 vaccination in South Korea between February 28 and August 21, 2021: A nationwide observational study
Dong Seok Lee[SUP] 1 [/SUP], Ji Won Kim[SUP] 2 [/SUP], Kook Lae Lee[SUP] 3 [/SUP], Yong Jin Jung[SUP] 4 [/SUP], Hyoun Woo Kang[SUP] 5 [/SUP]
Affiliations
- PMID: 35276381
- PMCID: PMC8904009
- DOI: 10.1016/j.ijid.2022.03.007
Abstract
Objectives: To investigate the clinical characteristics of adverse events following coronavirus disease 2019 (COVID-19) vaccination in patients in South Korea.
Design: Data from the Korean Disease Control and Prevention Agency on adverse events from four COVID-19 vaccines, including AZD1222, BNT162b2, JNJ-78436735, and mRNA-1273, from February 26 to August 21, 2021, were assessed. The epidemiological characteristics, clinical symptoms, severity, complications, and mortality were descriptively analyzed.
Results: Overall, 36.3 million individuals who completed the COVID-19 vaccination doses during the study period were included, and 153,183 adverse events were reported. Most adverse events occurred after the first dose (80.6%) and within a day (63.2%) following vaccination. Of the adverse events, 95.5% were non-severe cases; however, 4.5% were severe. Most of the mild adverse events showed a similar frequency across all age groups, but major severe adverse events and mortality events increased with age.
Conclusions: Although there were differences in the frequency of occurrence, various adverse reactions were confirmed in all four COVID-19 vaccines, even with the BNT162b2 (Pfizer-BioNTech) vaccine. Caution is needed, and further research should be continuously conducted.
Keywords: COVID-19 vaccines; SARS-CoV-2; adverse events; vaccine reactions.